Winstrol Inject
💉
Winstrol Inject Dragon Pharma
Stanozolol · DHT Injectable · No Aromatization · Pre-Contest · Less Hepatic Load
🧬
Class
DHT Derivative
injectable · water suspension
💉
Form / Strength
Aqueous suspension · 50 mg/ml
shake vial before use
⚗️
Aromatization
None
no AI required
🎯
Hepatic Load
Lower vs oral
bypasses first-pass liver
Typical Dose
50 mg/day
or 50 mg EOD
Route
Intramuscular
shake before drawing
Cycle Length
8–10 weeks
injectable = more room
Lab Tested
$40.00
$40.00
In Stock
Shipping
Winstrol Inject Dragon Pharma — Overview
Winstrol Inject Dragon Pharma is stanozolol in its injectable form — a 50 mg/ml aqueous suspension designed for intramuscular administration. The compound is chemically identical to oral stanozolol but the delivery route changes the pharmacological picture in one critical way: injected IM, stanozolol bypasses first-pass hepatic metabolism entirely. The liver does not process the dose before it enters systemic circulation, which produces a meaningfully lower hepatic burden at equivalent doses compared to any oral stanozolol format. This makes Winstrol Inject the preferred form for athletes who need an 8–10 week stanozolol protocol, for users managing liver enzyme levels, and for advanced competitors who want the full stanozolol profile with the lowest achievable oral hepatotoxicity. Steroid Warehouse carries Dragon Pharma's complete Winstrol line — oral and injectable — for complete cycle flexibility.
Stanozolol DHT Injectable Aqueous Suspension No Aromatization Reduced First-Pass Hepatic Load Pre-Contest & Cutting 8–10 Week Protocol
On this page
About the Compound: Injectable Stanozolol
Stanozolol is a DHT-derived anabolic-androgenic steroid with a pyrazole ring fused at the steroid A-ring. It does not aromatize to estrogen, does not retain water, and binds SHBG with exceptional affinity — displacing testosterone into free, receptor-active form at virtually any dose. These properties are consistent across all three Dragon Pharma Winstrol formats. What Winstrol Inject changes is the delivery mechanism and the resulting pharmacokinetics.
Active Substance
Stanozolol
Concentration
50 mg / ml
Carrier
Aqueous suspension
Half-Life (IM)
~24 hours
Aromatization
None
User Level
Intermediate–Advanced
- Water suspension vs oil-based injectables: Most injectable AAS are dissolved in an oil carrier (benzyl benzoate, sesame oil, MCT). Stanozolol is insoluble in oil at useful concentrations — it is instead suspended as micro-crystals in sterile water. This matters practically: the vial must be shaken thoroughly before drawing to re-suspend settled crystals. Injection consistency suffers if this step is skipped. Water-based suspensions also produce more injection site discomfort than oil-based compounds — a well-documented characteristic of this form.
- First-pass bypass and liver load: When administered IM, stanozolol enters the venous system directly and reaches systemic circulation without passing through hepatic portal metabolism first. This eliminates the primary hepatotoxic mechanism of oral stanozolol. The 17α-methyl group is still present — stanozolol is still technically 17α-alkylated — but without first-pass processing the hepatic load is substantially reduced. ALT/AST elevation is typically lower at equivalent doses compared to oral formats, and the 8–10 week cycle window reflects this advantage.
- Half-life and dosing frequency: The intramuscular half-life is approximately 24 hours — significantly longer than the 9-hour oral half-life. Daily injections (50 mg/day) maintain near-stable blood levels. Some users run 50 mg every other day (EOD), which reduces injection frequency at a modest reduction in peak plasma concentration. Both protocols are practical.
What Winstrol Inject Does
- Muscle hardness and definition: The same surface-hardening effect that characterizes all stanozolol formats — water cleared, subcutaneous fluid minimized, muscle tissue appearing tighter and denser against the skin. With an injectable protocol running 8–10 weeks, this effect accumulates over a longer timeline than the oral 6–8 week maximum, giving a more gradual and sustained transformation through the pre-contest period.
- Strength without weight gain: Stanozolol increases strength and power output without adding bodyweight. This property is consistent across oral and injectable forms. The injectable half-life produces a smoother strength profile than the oral's peak-and-trough curve, which some athletes prefer during high-performance training blocks.
- SHBG displacement: Free testosterone availability increases at all stanozolol doses through competitive SHBG displacement. With a 24-hour injectable half-life, this effect is sustained more consistently across the day than with oral dosing, potentially enhancing synergy with any testosterone compound in the stack.
- Lean mass preservation during a caloric deficit: Anti-catabolic action is equivalent to the oral form at matched doses. Over a longer cycle window (8–10 weeks), the injectable format provides sustained muscle protection through deeper cuts without the liver constraint that forces oral protocols to terminate at 8 weeks.
- No estrogen-related effects: Stanozolol does not aromatize regardless of route of administration. Water retention, gynecomastia, and estrogen-mediated fat distribution do not occur from the compound itself. No aromatase inhibitor is required unless another compound in the stack aromatizes.
Who It's For
Winstrol Inject occupies a specific niche in the stanozolol product line — not a beginner format, not a women's format, but the performance-optimized choice for users who want the stanozolol effect profile with reduced hepatic compromise.
- What differentiates Winstrol Inject from similar options: The injectable form is the only stanozolol format that removes first-pass liver metabolism from the equation — producing a longer viable cycle (8–10 weeks versus 6–8 oral), lower ALT/AST burden at equivalent doses, and a ~24-hour half-life that enables consistent blood levels without twice-daily dosing. No oral stanozolol format provides these pharmacokinetic properties regardless of dose.
- The specific scenario where it's the better choice: Athletes running contest prep cycles of 8–10 weeks who cannot afford to terminate the stanozolol protocol early due to liver pressure. Users whose mid-cycle bloodwork shows ALT/AST elevation on oral stanozolol who want to continue the protocol. Advanced competitors who run multiple compounds simultaneously and want to minimize the total oral hepatotoxic load. Any user who is comfortable with intramuscular injection and prioritizes compound longevity over injection convenience.
- Who should choose something else: Users who are not experienced with intramuscular injections — water suspension injections are more painful than oil-based compounds, and this is not the format to learn injection technique on. Women should use Winstrol 10 at 5–10 mg/day. Users who have no hepatic concern and prefer oral convenience should choose Winstrol 50. Anyone wanting a dry injectable cutting compound with no collagen inhibition concern should evaluate Masteron 100 — it does not affect joint collagen the way stanozolol does.
Winstrol Inject vs Alternatives
| Compound | Key Differences | Choose Winstrol Inject When | Choose Alternative When |
|---|---|---|---|
| Winstrol Inject (Stanozolol 50 mg/ml) | Injectable water suspension; no first-pass hepatic metabolism; ~24 hr IM half-life; 8–10 week cycle viable; injection site discomfort notable with water suspension | Minimizing oral hepatic load; cycle length >8 weeks; consistent blood levels preferred; comfortable with IM injection | — |
| Winstrol 50 (Stanozolol 50 mg/tab) | Same compound; oral tablet; first-pass hepatic metabolism; ~9 hr half-life; 6–8 week maximum; no injection; higher hepatic load per equivalent dose | — | Injection experience absent or undesirable; cycle under 8 weeks; oral convenience preferred; hepatic concern is low |
| Masteron 100 (Drostanolone Propionate 100 mg/ml) | Different compound (DHT derivative, oil-based, ester-bound); no collagen synthesis inhibition — joints are not affected; androgenic hardness different character from stanozolol; no SHBG reduction comparable to stanozolol; natural anti-estrogen properties; more comfortable injection | — | Joint dryness and pain from stanozolol is a cycle-limiting problem; oil-based injection comfort preferred; androgenic hardness without SHBG displacement is the goal |
| Primobolan 100 (Methenolone Enanthate 100 mg/ml) | Different compound (DHT derivative, oil-based); very low androgenic activity; extremely mild side effect profile; minimal HPG suppression at moderate doses; no joint collagen inhibition; higher cost per effective dose; less surface hardening than stanozolol | — | Side effect minimization is the priority; androgenic effects need to stay low (sensitivity, hair loss concern); mild lean mass preservation with minimal suppression is the goal |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Extended cutting cycle (8–10 wks) | Winstrol Inject (50 mg/day) + Enantat 250 |
The primary use case for the injectable form: stanozolol runs the full cycle alongside a testosterone enanthate base without the 8-week oral liver limit forcing an early stop. Enantat 250 provides hormonal balance, prevents suppression-related muscle loss, and benefits from stanozolol's SHBG-freeing effect throughout the extended cycle. |
| Pre-contest hardening (final 6–8 wks) | Winstrol Inject (50 mg/day) + Propionat 100 + Masteron 100 |
Three injectable dry compounds with complementary mechanisms. Propionat provides precise water control with its short ester. Masteron adds androgenic density and natural anti-estrogenic properties. Winstrol Inject brings surface dryness and SHBG displacement. All injectable — total hepatic load lower than running oral stanozolol in this stack. |
| Low-androgenic lean cycle | Winstrol Inject (50 mg EOD) + Primobolan 200 |
Two mild injectable compounds for users managing androgenic side effects. Primobolan 200 at standard doses provides lean anabolic support with minimal androgenic activity and low suppression. Winstrol Inject at 50 mg EOD adds surface hardness and SHBG reduction without stacking a high-androgenic compound. Combined androgenic burden is lower than any testosterone-based stack. |
| Recomp stack | Winstrol Inject (50 mg/day) + Masteron 200 + Enantat 250 |
All three injectable — no oral hepatic load in the stack. Enantat 250 provides the anabolic base and HPG protection. Masteron 200 delivers sustained androgenic hardness with longer dosing intervals. Winstrol Inject completes the triad with dryness and SHBG optimization. A full recomp or late-phase cutting stack with no tablets required. |
| Strength sports (weight class) | Winstrol Inject (50 mg EOD) + Propionat 100 |
EOD injection schedule at 50 mg/dose gives consistent blood levels while reducing daily injection burden — practical for athletes with demanding training schedules. Propionat controls water accumulation precisely. Winstrol Inject provides strength without weight and can run 8–10 weeks to cover a full competition preparation block. |
Side Effects and How to Manage Them
Winstrol Inject shares stanozolol's complete side effect profile — the injectable route reduces but does not eliminate hepatic and androgenic risks. Joint dryness deserves particular attention with this format: at 50 mg/day for 8–10 weeks, cumulative collagen inhibition is longer-duration than any oral protocol, and joint discomfort can progress over time rather than appearing acutely.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Hepatotoxicity (ALT/AST elevation — reduced vs oral) | First-pass bypass substantially lowers hepatic stress compared to oral stanozolol at equivalent doses. ALT/AST elevation still occurs — stanozolol is intrinsically 17α-alkylated — but is typically less severe and more compatible with longer cycles. The 8–10 week window exists because of this advantage, not because hepatotoxicity is absent. | Liv.52, NAC (Mucinac), and UDCA (Ursocol) throughout the cycle. ALT/AST check at week 4–5. The injectable advantage does not eliminate the need for liver support — it widens the safety window for running it longer. |
| Joint dryness and arthralgic pain (extended timeline) | Stanozolol's inhibition of collagen synthesis and reduction of synovial fluid applies to the injectable form equally — the mechanism is systemic, not first-pass dependent. At 8–10 weeks the cumulative joint exposure is longer than any oral protocol. Shoulders, elbows, and knees are the most commonly affected joints, especially under high training loads. Some users find injectable stanozolol produces different joint symptom intensity than oral; others report equivalent discomfort at matched doses. | Monitor joint comfort from week 4 onward — this is where cumulative collagen inhibition becomes symptomatic in longer cycles. Reduce to 50 mg EOD if pain develops at daily dosing. Reduce training load on high-stress joint movements. If joint symptoms are cycle-limiting, Masteron 100 does not share stanozolol's collagen pathway and can serve as a replacement dry compound in subsequent cycles. |
| Injection site reactions | Water-based suspensions are inherently more irritating at the injection site than oil-based compounds. Stanozolol micro-crystals in the suspension trigger a local inflammatory response — manifesting as injection site pain, swelling, or warmth lasting 24–72 hours after administration. This is a known property of the formulation, not a contamination or immune reaction. | Shake the vial for 60 seconds before drawing — unsettled crystals increase irritation. Use a 23–25 gauge needle for administration; water suspension does not require the larger gauges used with viscous oils. Rotate injection sites systematically: glutes, quads, and delts. Warm the syringe to body temperature before injection. Accept that some site discomfort is inherent to this format — persistent severe swelling warrants stopping. |
| HDL suppression / lipid dysregulation | HDL suppression is stanozolol-specific — it occurs regardless of route of administration and is among the most pronounced of any AAS. At 8–10 weeks of 50 mg/day the cumulative lipid impact is higher than a shorter oral cycle. This is the most significant long-term cardiovascular risk of this compound. | Lipid panel before cycle and mid-cycle (week 5). Atorvastatin if LDL elevation accompanies HDL suppression. Allow full lipid normalization before the next cycle. Diet: maintain omega-3-rich food intake throughout. |
| Hair loss acceleration | DHT-derived compound, resistant to 5α-reductase inhibition — finasteride does not block stanozolol's follicular androgenic action. At 8–10 weeks continuous exposure, genetically susceptible users experience more cumulative hair follicle miniaturization than a 6-week oral protocol produces. | Minoxidil topically throughout the cycle. Reduce to EOD dosing if hair shedding is significant. Users with strong genetic predisposition should evaluate whether stanozolol at this duration is compatible with their hair retention goals. |
| Acne | Androgenic sebaceous gland stimulation — back and shoulders most common sites. Over an 8–10 week cycle, acne can progress in severity through sustained androgenic exposure. | Topical benzoyl peroxide or salicylic acid for mild-moderate cases. Accutane (Isotretinoin) for severe or persistent presentations at the prescribing threshold. |
| HPG axis suppression | Stanozolol suppresses LH, FSH, and endogenous testosterone regardless of route of administration. An 8–10 week injectable cycle produces deeper and longer-duration suppression than a 6-week oral protocol — PCT planning should account for this. | HCG in the final 1–2 weeks of cycle before transitioning to SERM-based PCT. See Post-Cycle Recovery section. |
| Blood pressure elevation | Androgenic compounds and HDL-driven cardiovascular changes both contribute. Over an extended injectable cycle these pressures compound — more monitoring intervals are warranted than for a short oral protocol. | Amlodipine (Amlip) or Telmisartan (Sartel) if readings exceed 135/85 mmHg. Ecosprin (Aspirin) 75 mg/day throughout. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| ALT / AST | Before cycle; week 4–5 (mid-point); end of cycle | <3× upper limit of normal. Injectable stanozolol typically produces lower elevation than oral at equivalent doses — but the longer cycle means monitoring mid-cycle matters more, not less. |
| Lipid panel (HDL / LDL) | Before cycle; week 5; end of cycle | HDL >40 mg/dL; LDL <130 mg/dL. An 8–10 week cycle warrants a mid-cycle lipid check — HDL recovery does not happen during the cycle and continued suppression over 10 weeks compounds cardiovascular risk. Add Atorvastatin if LDL >160 mg/dL. |
| Hematocrit / CBC | Before cycle; end of cycle | Hematocrit <52% (male). Stanozolol stimulates erythropoiesis; over 8–10 weeks this effect accumulates. |
| Blood pressure | Every 2 weeks during cycle | <135/85 mmHg. Over a longer cycle the BP monitoring schedule matters — do not extend intervals beyond 2 weeks. |
| LH + FSH | 4–6 weeks post-PCT | Return toward baseline confirms HPG recovery. Deeper suppression from a longer cycle may require extended PCT before LH/FSH normalize. |
| Total testosterone | End of PCT | Recovery to pre-cycle baseline. After an 8–10 week cycle, full recovery may take longer than after a shorter oral protocol — confirm before planning the next cycle. |
Post-Cycle Recovery
Injectable stanozolol's ~24-hour half-life means a short washout before PCT begins. After the last injection, allow 2–3 days before starting SERM-based PCT to let stanozolol clear to supratherapeutic levels. HCG in the final 1–2 weeks of the cycle is especially important after an 8–10 week injectable protocol.
| Product | Role in PCT |
|---|---|
| Nolvadex (Tamoxifen) | Primary SERM backbone. Pituitary estrogen receptor blockade restores LH/FSH release and restarts endogenous testosterone production. Standard first-line PCT agent. |
| Clomid (Clomiphene) | Combined with Nolvadex for the first 2–3 weeks when HPG suppression from an extended injectable cycle requires more aggressive gonadotropin stimulation to restart. |
| HCG 5000 IU | Run in the final 1–2 weeks of the cycle before PCT begins. After 8–10 weeks of suppression, HCG prevents testicular atrophy and maintains Leydig cell sensitivity — critical preparation for effective SERM-based recovery. |
| Enclomiphene | Clean Clomid alternative with fewer mood and vision side effects. Useful for users who find standard clomiphene poorly tolerated during the recovery phase of an extended cycle. |
For full PCT timing and dosing protocols see the PCT guide.
Practical Summary — Winstrol Inject Dragon Pharma
- Shake the vial for 60 seconds every time before drawing — stanozolol crystals settle; an unshaken vial gives an inconsistent dose and increases injection site irritation
- The injectable form's liver advantage is real but not a blank cheque — run liver support throughout (Liv.52 + NAC + UDCA) and check ALT/AST at week 4–5; the 8–10 week window requires this, it is not automatic
- HDL suppression is route-independent — a mid-cycle lipid panel at week 5 is warranted on an extended injectable cycle, not just pre- and post-cycle
- Joint dryness accumulates over time — monitor from week 4 onward; if shoulder or elbow pain develops, drop to 50 mg EOD before it becomes cycle-limiting
- Injection discomfort with water suspension is normal; warm the syringe to body temperature, use a 23–25 gauge needle, and rotate sites consistently across glutes, quads, and delts
- PCT timing after the last injection: allow 2–3 days for stanozolol to clear, then begin SERMs — HCG in the final cycle week is essential after a protocol of this length
Winstrol Inject occupies a precise position in the stanozolol product range: the same reliable cutting and hardening compound as the oral tablets, but delivered in a form that removes the primary liver metabolism constraint. For athletes who run stanozolol as a core pre-contest tool and need 8–10 weeks of uninterrupted use, steroidwarehouse.com's injectable stanozolol from Dragon Pharma provides that extended window without forcing a compromise on the compound itself. The injection site discomfort is the trade-off; for most experienced competitors, it is a straightforward one to accept.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks in healthy men; showed increased fat-free mass, muscle size, and strength, with the largest gains when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, medical uses, misuse patterns, oral and injectable AAS forms, monitoring concerns, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — detailed medical overview of testosterone, dihydrotestosterone, androgen receptor signaling, aromatization to estradiol, HPG-axis regulation, synthetic androgen use, and misuse-related endocrine suppression | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic steroid pharmacology; covers androgen receptor mechanisms, testosterone derivatives, injectable and oral AAS classes, metabolism, anabolic-androgenic effects, misuse context, detection issues, and adverse health risks | Kicman AT (2008) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — comprehensive review of anabolic-androgenic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, liver effects, and psychological considerations | Hartgens F & Kuipers H (2004) ↗ |
What is Winstrol Inject?
Winstrol Inject is an injectable anabolic steroid (Stanozolol) for lean muscle; see What is Winstrol Inject. It's potent—consult professionals for safe use.
What does Winstrol Inject do?
It promotes lean muscle, strength, and fat loss; see What Does Winstrol Inject Do. It enhances definition—monitor with labs.
Does Winstrol Inject burn fat?
Yes, it supports fat loss by enhancing metabolism; see Does Winstrol Inject Burn Fat. Use with diet—consult professionals.
How long does Winstrol Inject stay in your system?
It's detectable for ~2 months; see How Long Does Winstrol Inject Stay in Your System. Monitor with professional guidance.
What is Winstrol Inject used for in bodybuilding?
It's used for cutting, lean muscle, and definition; see What is Winstrol Inject Used For in Bodybuilding. It suits cutting cycles—use with oversight.
How to take Winstrol Inject?
50-100 mg EOD for men, 10-25 mg EOD for women; see How to Take Winstrol Inject. Start low—consult professionals for dosing.
How long does it take to notice effects from Winstrol Inj?
Users often report gradual improvements in muscle hardness, strength, and overall physique appearance within several weeks of consistent use.
Is Winstrol Inj better for bulking or cutting?
Winstrol Inj is most commonly associated with cutting and recomposition phases due to its reputation for promoting a lean, hard, and defined physique with minimal water retention.
Related Products
Available Domestic
Lab Tested
Anavar 50 Dragon Pharma
Oxandrolone 50 mg · DHT-derived oral AAS · non-aromatizing
Class
DHT-Derived
Oral AAS
Form / Active Life
No ester
~9 hours · dose twice daily
Aromatization
None
No estrogen conversion
User Level
Intermediate
to Advanced
Typical Dose
50–100 mg
per day (men)
Frequency
N/A (oral)
1–2 tabs daily, split dose
Cycle Length
6–8 weeks
typical range
Available Domestic
Best Seller
Lab Tested
Cypionat 250 Dragon Pharma
Testosterone Cypionate · 250 mg/ml · Long-ester injectable
Class
Anabolic Steroid
injectable testosterone ester
Half-life
~8 days
twice-weekly injection
Context
Bulking · TRT
mass, strength, hormone base
Administration
IM injection
glute, quad, or delt
Typical Dose
250–500 mg/wk
1–2 ml per week
Frequency
2× per week
Mon / Thu split
Cycle Length
12–16 weeks
PCT required after
Available Domestic
Best Seller
Lab Tested
Enantat 250 Dragon Pharma
Testosterone Enanthate 250 mg/mL · Long-Ester Injectable · high aromatization
Class
Androgenic-Anabolic
Testosterone / Enanthate ester
Ester / Active Life
Enanthate (C8)
~4.5 day t½ · 8–10 days active
Aromatization
High
AI required from day 1
User Level
Beginner
to Advanced
Typical Dose
250–750 mg
per week
Injection Frequency
E7D or E3.5D
once or twice weekly
Cycle Length
10–16 weeks
PCT 14 days after last pin
Lab Tested
NPP 150 Dragon Pharma
Nandrolone Phenylpropionate · 19-nor AAS · 150 mg/ml · lean mass & joint support
Class
19-nor AAS
nandrolone phenylpropionate
Anabolic / Androgenic
125 / 37
high anabolic, low androgenic
Half-Life
~4–5 days
inject EOD or E3D
Concentration
150 mg/ml
1 ml = 150 mg
Weekly Dose
300–500 mg
typical working range
Stack Rule
Always + Test
never run solo
Cycle Length
10–12 wk
typical
PCT Start
~7 days
after last pin
Prolactin
Monitor
cabergoline on hand
Lab Tested
💉
Trenbolone 100 Dragon Pharma
Trenbolone Acetate 100 mg/ml · 19-Nor · Advanced · Short Ester
🧬
Class
19-Nor / Trenbolone
AR affinity ~5× testosterone
⏱️
Ester / Active Life
Acetate · ~2–3 days
EOD injections · fast clearance
✅
Aromatization
None — no E2 conversion
progestogenic · Caber required
🎯
User Level
Advanced
first tren ester of choice
Typical Dose
50–100 mg/injection
~175–350 mg/week at EOD
Injection Frequency
EOD
every other day (acetate)
Cycle Length
8–10 weeks
short-ester protocol